New York, Assurex Health announced today that it has secured $15 million in equity financing from Series D investors. Investors included existing shareholders Sequoia Capital, Claremont Creek Ventures, Cincinnati Children’s Hospital Medical Center, Mayo Clinic, and Cross Creek Advisors, among others.
Assurex Health is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping healthcare providers get the genetic information they need to determine the right medication for individual patients suffering from neuropsychiatric and other medical conditions. Assurex Health’s proprietary technology is based on pharmacogenomics— the study of the genetic factors that influence an individual’s response to drug treatments—as well as evidence-based medicine and clinical pharmacology.
The GeneSight test was developed in the Assurex Health clinical laboratory and is based on patented technology licensed from two world renowned medical centers, Mayo Clinic and Cincinnati Children’s Hospital Medical Center, who continue to be research collaborators.